Targeting pericellular proteolysis in vascular disease.
Bendeck
Michelle P
MP
D004789:Enzyme Activation / Q000187:drug effects; D005109:Extracellular Matrix / Q000378:metabolism*; D006083:Graft Occlusion, Vascular / Q000503:physiopathology; D006801:Humans; D020782:Matrix Metalloproteinases / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism*; D010960:Plasminogen Activators / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000494:pharmacology; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000235:genetics; D017539:Tunica Intima / Q000503:physiopathology; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics; D014652:Vascular Diseases / Q000503:physiopathology*
D011993:Recombinant Fusion Proteins; D019715:Tissue Inhibitor of Metalloproteinase-1; D010447:Peptide Hydrolases; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; D020782:Matrix Metalloproteinases